CD133 is a transmembrane glycoprotein also known as Prominin 1. It is often used as a biomarker for CSC enrichment in cancer, as it targets a subset of cancer cells that show a drug-resistant phenotype and an increased tumor-initiating ability in xenotransplantation assays [67]. Here, PROM1 is linked to cancer.